je.st
news
Home
› RXi Pharmaceuticals Announces Completion of Enrollment in Second Phase 1 Trial for RXI-109 Program
RXi Pharmaceuticals Announces Completion of Enrollment in Second Phase 1 Trial for RXI-109 Program
2013-01-31 09:52:58| Biotech - Topix.net
RXi Pharmaceuticals Corporation , a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that its second Phase 1 study with their anti-scarring drug, RXI-109, for the management of surgical and hypertrophic scars and ... (more)
Tags: program
trial
phase
completion
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||